Riccardo Panella and Simone Tomasini from the Center for RNA Medicine (CRM) attended the Keystone Symposium on Metabolic and Molecular Mechanisms of NAFLD/NASH in March 19-23, 2023 in Fairmont Banff Springs, Alberta, Canada. Non-alcoholic steatohepatitis (NASH) represents the hepatic manifestation of the Metabolic Syndrome and is emerging as a key driver of morbidity and mortality, especially in the context of liver fibrosis. The Keystone Conference brought together a broad group of researchers to discuss recent evidence exploring the key biological processes involved in #NASH and liver fibrosis. Furthermore, as NASH represents a high unmet medical need, recent updates in the clinical development of new therapies to tackle NASH and liver fibrosis were presented. Riccardo Panella and Simone Tomasini presented a poster entitled “miR-22 represents a key regulator of lipid homeostasis and a therapeutic target in NAFLD and obesity”, which was well received and triggered good discussions with the scientific and clinical researchers in the field.
